| 57.1 1.46 (2.62%) | 05-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 69.84 | 1-year : | 73.94 |
| Resists | First : | 59.8 | Second : | 63.31 |
| Pivot price | 59.28 |
|||
| Supports | First : | 54.12 | Second : | 45.03 |
| MAs | MA(5) : | 57.08 |
MA(20) : | 59.84 |
| MA(100) : | 54.44 |
MA(250) : | 43.95 |
|
| MACD | MACD : | -0.5 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 27.2 |
D(3) : | 22.4 |
| RSI | RSI(14): 44.7 |
|||
| 52-week | High : | 65 | Low : | 28.63 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PCVX ] has closed above bottom band by 23.5%. Bollinger Bands are 3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 57.38 - 57.78 | 57.78 - 58.1 |
| Low: | 54.33 - 54.75 | 54.75 - 55.08 |
| Close: | 56.54 - 57.2 | 57.2 - 57.72 |
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Wed, 06 May 2026
Higher Vaxcyte (NASDAQ: PCVX) Q1 loss as late-stage trials expand - Stock Titan
Wed, 06 May 2026
Vaxcyte (NASDAQ: PCVX) advances Phase 3 VAX-31 program and holds $2.7B cash - Stock Titan
Wed, 06 May 2026
Vaxcyte completes three Phase 3 vaccine enrollments; Q4 data next - Stock Titan
Wed, 06 May 2026
FMR LLC discloses 11.4% stake in Vaxcyte (NASDAQ: PCVX) - Stock Titan
Sat, 02 May 2026
Insider Sell Alert: Jim Wassil Sells Shares of Vaxcyte Inc (PCVX) - GuruFocus
Fri, 01 May 2026
Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 144 (M) |
| Shares Float | 132 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 104 (%) |
| Shares Short | 14,360 (K) |
| Shares Short P.Month | 13,070 (K) |
| EPS | -5.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 20.48 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -17.8 % |
| Return on Equity (ttm) | -25.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -656 (M) |
| Levered Free Cash Flow | -431 (M) |
| PE Ratio | -10.15 |
| PEG Ratio | 0 |
| Price to Book value | 2.78 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|